Organon (OGN.US) suffered a severe setback due to internal control issues, and Piper Sandler slashed its target price to $5

Zhitongcaijing · 10/28/2025 07:01

The Zhitong Finance App learned that Piper Sandler downgraded Organon (OGN.US)'s rating from “plus” to “less” and lowered the target share price from $18 to $5. The action follows an investigation of the company by the Board of Auditors, which revealed significant internal control flaws in the company's contraceptive product “Non,” which led to misstatements in the 2022, 2024, and 2025 financial statements. The company's stock price closed down about 23% on Monday.

This downgrade shows that Piper Sandler believes Organon has a long road to recovery, mainly due to the need to restore internal controls and investor confidence. Analysts also warned investors that risk and volatility are likely to increase given the current uncertainty and the company's lengthy and challenging process to turn losses into profits.